Kyverna Therapeutics Inc (KYTX)

$5.01 +0.64 (14.65%)
Market Cap 167.36M
Revenue (ttm) 0.00
Net Income (ttm) -127.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 762,600
Avg Vol 311,488
Day's Range N/A - N/A
Shares Out 43.25M
Stochastic %K 92%
Beta 3.08
Analysts Strong Sell
Price Target $18.20

Company Profile

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, lupus nephritis, and rapid whole blood process. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an alloge...

Industry: Biotechnology
Sector: Healthcare
Phone: (510) 925-2492
Address:
5980 Horton Street, Suite 550, Emeryville, United States
Paciorr
Paciorr Sep. 18 at 5:35 PM
$KYTX Sold at $4.8 thinking it gotta dip. Welp... Maybe tomorrow or next week
1 · Reply
mmtiddy
mmtiddy Sep. 18 at 5:25 PM
$KYTX Wow!
0 · Reply
biospeculator
biospeculator Sep. 17 at 8:18 PM
$KYTX I bought 10k this morning based on both technicals and fundamentals and am now bringing it to the attention of several other traders. The MACD appears ready to break $4.5 resistance imo with an immediate target of $6-$8 and then $14. Between the small float and large institutional and insider ownership the stock is very thin. Any good news should get us to the targets mentioned. GLTA
0 · Reply
SweSapiens
SweSapiens Sep. 17 at 6:28 PM
$KYTX let’s see how many times we can test and reject off $4,40
3 · Reply
ThomasTrainTrader
ThomasTrainTrader Sep. 17 at 4:17 PM
$KYTX Sniped
0 · Reply
ThomasTrainTrader
ThomasTrainTrader Sep. 16 at 7:30 PM
$KYTX CABA once again is valued $14 million more than Kyverna. All while having $17 million less cash on hand and also being significantly behind in trial timelines, manufacturing capabilities, industry partnerships and safety profiles. This kind of delta never lasts for more than a couple days
0 · Reply
prismmarketview
prismmarketview Sep. 15 at 5:59 PM
(NASDAQ: $KYTX) Kyverna Therapeutics highlights interim Phase 2 data for KYV-101 in gMG at AANEM2025. Safety + efficacy signals support its registrational Phase 2/3 trial, with Phase 3 start expected by year-end. https://prismmarketview.com/all-eyes-on-kyverna-as-interim-kyv-101-results-headline-aanem-meeting/
0 · Reply
G101SPM
G101SPM Sep. 15 at 5:07 PM
Holds long position $KYTX $3.92 Kyverna Therapeutics to highlight interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 (3.93 +0.01) Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up. Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025. https://stocktwits.com/G101SPM/message/627987167
1 · Reply
Paciorr
Paciorr Sep. 14 at 12:43 PM
$KYTX Does anyone have a catalysts/news calendar or something?
1 · Reply
ThomasTrainTrader
ThomasTrainTrader Sep. 12 at 8:07 PM
$KYTX Bought another $2K today near the lows
0 · Reply
Latest News on KYTX
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Sep 15, 2025, 1:02 PM EDT - 3 days ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 28, 2025, 8:00 AM EDT - 21 days ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 25, 2025, 4:02 PM EDT - 24 days ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

Aug 20, 2025, 3:29 PM EDT - 4 weeks ago

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 4:02 PM EDT - 5 weeks ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Jul 29, 2025, 8:30 AM EDT - 7 weeks ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 4:02 PM EDT - 4 months ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

May 27, 2025, 3:42 PM EDT - 4 months ago

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:02 PM EDT - 4 months ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 4:02 PM EDT - 6 months ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Mar 21, 2025, 11:29 AM EDT - 6 months ago

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Mar 3, 2025, 4:05 PM EST - 7 months ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Feb 7, 2025, 11:42 AM EST - 7 months ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

Feb 6, 2025, 1:51 PM EST - 8 months ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Feb 5, 2025, 11:54 AM EST - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX

Feb 4, 2025, 3:51 AM EST - 8 months ago

Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Jan 27, 2025, 3:22 PM EST - 8 months ago

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Jan 21, 2025, 4:05 PM EST - 8 months ago

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 7:30 AM EST - 8 months ago

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Paciorr
Paciorr Sep. 18 at 5:35 PM
$KYTX Sold at $4.8 thinking it gotta dip. Welp... Maybe tomorrow or next week
1 · Reply
mmtiddy
mmtiddy Sep. 18 at 5:25 PM
$KYTX Wow!
0 · Reply
biospeculator
biospeculator Sep. 17 at 8:18 PM
$KYTX I bought 10k this morning based on both technicals and fundamentals and am now bringing it to the attention of several other traders. The MACD appears ready to break $4.5 resistance imo with an immediate target of $6-$8 and then $14. Between the small float and large institutional and insider ownership the stock is very thin. Any good news should get us to the targets mentioned. GLTA
0 · Reply
SweSapiens
SweSapiens Sep. 17 at 6:28 PM
$KYTX let’s see how many times we can test and reject off $4,40
3 · Reply
ThomasTrainTrader
ThomasTrainTrader Sep. 17 at 4:17 PM
$KYTX Sniped
0 · Reply
ThomasTrainTrader
ThomasTrainTrader Sep. 16 at 7:30 PM
$KYTX CABA once again is valued $14 million more than Kyverna. All while having $17 million less cash on hand and also being significantly behind in trial timelines, manufacturing capabilities, industry partnerships and safety profiles. This kind of delta never lasts for more than a couple days
0 · Reply
prismmarketview
prismmarketview Sep. 15 at 5:59 PM
(NASDAQ: $KYTX) Kyverna Therapeutics highlights interim Phase 2 data for KYV-101 in gMG at AANEM2025. Safety + efficacy signals support its registrational Phase 2/3 trial, with Phase 3 start expected by year-end. https://prismmarketview.com/all-eyes-on-kyverna-as-interim-kyv-101-results-headline-aanem-meeting/
0 · Reply
G101SPM
G101SPM Sep. 15 at 5:07 PM
Holds long position $KYTX $3.92 Kyverna Therapeutics to highlight interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 (3.93 +0.01) Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up. Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025. https://stocktwits.com/G101SPM/message/627987167
1 · Reply
Paciorr
Paciorr Sep. 14 at 12:43 PM
$KYTX Does anyone have a catalysts/news calendar or something?
1 · Reply
ThomasTrainTrader
ThomasTrainTrader Sep. 12 at 8:07 PM
$KYTX Bought another $2K today near the lows
0 · Reply
Bigbucksnow
Bigbucksnow Sep. 12 at 2:38 AM
$KYTX
0 · Reply
G101SPM
G101SPM Sep. 9 at 3:19 PM
G101SPM 8/28/2025, 2:23:05 PM $KYTX $3.71 ask. BUY/2X ADD TO LONG POSITION as SPM tag remains position to EXIT point. DAC (dollar average cost includes this BUY representing the third transaction). (4) $4.785. EXIT $18.00 (long term).
0 · Reply
mmtiddy
mmtiddy Sep. 6 at 11:54 AM
$KYTX Still holding, lottery ticket for me, if this gets new this has a huge gap up
0 · Reply
StreetwiseReports
StreetwiseReports Sep. 5 at 5:51 PM
New Remission Data on MG Patients Compelling https://ow.ly/58Xu50WS8v5 Kyverna Therapeutics Inc.'s KYV-101 cell therapy drives a 15-month and longer remission in three patients treated on a compassionate use basis, noted an H.C. Wainwright & Co. report. $KYTX
0 · Reply
StreetwiseReports
StreetwiseReports Sep. 3 at 10:55 PM
Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial https://ow.ly/hcci50WQRMs Kyverna Therapeutics Inc. unveiled the design of its U.S. registrational Phase 3 trial for KYV-101 in myasthenia gravis during a Key Opinion Leader event, following ≥ 15-month remission data in Germany. Read more to see what sets this trial apart. $KYTX
0 · Reply
ThomasTrainTrader
ThomasTrainTrader Aug. 29 at 6:25 PM
$KYTX huge since HC Wainwright was directly invested against Kyvernas interests previously with CABA
0 · Reply
JarvisFlow
JarvisFlow Aug. 29 at 1:00 PM
HC Wainwright & Co. updates rating for Kyverna Therapeutics ( $KYTX ) to Buy, target set at 5 → 10.
0 · Reply
BluntForceOptions
BluntForceOptions Aug. 27 at 9:14 PM
$KYTX ICYMI: Kyverna announced that CEO Warner Biddle will present at three upcoming investor conferences in September: Wells Fargo (Sep 3), Morgan Stanley (Sep 8), and H.C. Wainwright (Sep 9). All three appearances are in a fireside chat format, with live webcasts and replays available on the company’s website. A busy lineup that should give the Street more visibility into the story. Stay tuned!
0 · Reply
YoloAlfred
YoloAlfred Aug. 26 at 4:48 PM
$KYTX 🤔🤔🤔🤔
1 · Reply
DonMclean64
DonMclean64 Aug. 25 at 1:42 PM
$KYTX if it breaks 4 it’ll move
0 · Reply
Zweagel91
Zweagel91 Aug. 25 at 9:55 AM
$KYTX https://www.investing.com/news/analyst-ratings/william-blair-initiates-coverage-on-kyverna-therapeutics-stock-with-outperform-rating-93CH-4201557
0 · Reply
Quantumup
Quantumup Aug. 22 at 6:41 PM
Cantor reit $DNTH OW-Top Pick ~sees clear opp for Tx if TPP is achieved - room for multi-players/Blockbusters. $ARGX $AZN $UCBJY $REGN $KYTX Guggenheim, on 8/14, reit $DNTH Buy-$92-Top Pick ~believes a PBO-adj'd ≥1.8 reduction in MG-ADL is achievable after leveraging data from 12 recent P II/III gMG studies - R/R +100%/-50%. Cantor and Guggenheim said their notes:
1 · Reply